Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Radiofrequency Renal Denervation in Drug Resistant Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 80 years at time of randomization~* Informed consent~* Treatment with full doses of 3 or more anti-hypertensive medications of different classes, of which one is a diuretic.~* Office Systolic BP (SBP) ≥ 160 mmHg or Diastolic BP (DBP) ≥ 100 mmHg~Exclusion Criteria:~* An estimated glomerular filtration rate (eGFR) of \< 30 mL/min/1.73 m2~* Ambulatory Blood Pressure Monitoring (ABPM) 24 hour average SBP \< 135 mmHg or DBP \< 85 mmHg~* Symptomatic(secondary) hypertension~* Severe renal artery stenosis or renal arteries abnormalities~* Individual is pregnant, nursing or planning to be pregnant~* Severe hepatic dysfunction~* Any other clinically important renal, hematological, metabolic, neurological, gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study participation (investigator's assessment)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Renal denervation (Type: EXPERIMENTAL): All eligible patients undergo bilateral radiofrequency sympathetic renal denervation using endocardial ablation system: after standard renal angiography using femoral access a small size endocardial ablation catheter (5-6 F, 4 mm electrode) is inserted into renal artery and 4-8 point ablations are performed consecutively from distal part to aorta with 3-4 mm step and 90 degrees rotation on the upper, lower, front and back aspects of the artery to get circumferential coverage, then the procedure is repeated on the other side.

Based on this trial design, predict the completion outcome and termination type (if applicable).